In Silico Development of Anticancer Drugs

Abstract

The development of new drugs has been recognised as a complex, costly, time-consuming, and difficult enterprise. A new medication discovery via typical drugdevelopment pipeline is predicted to take around 12 years and 2.7 billion USD on average. Methods to cut research costs and accelerate the development process of new drugs has become a difficult and pressing topic for the pharmaceutical sector. Computer-aided drug discovery (CADD) has developed as a potent and promising technique for designing drugs that are quicker, cheaper, and more effective. Recently, the fast development of computational techniques for drug discovery, particularly anticancertherapies, has had a substantial and exceptional influence on anticancer medication design, as well as beneficial insights into the field of cancer therapy.This article describes docking of Crizotinib, Sunitinibmalate, and their analogues with the Anaplastic lymphoma kinase receptor.On docking with the Anaplastic lymphoma kinase receptor, Crizotinib and Sunitinibmalate yielded energy values of -9.85 and -8.25, respectively.